Abstract

PEPTIDE-OLIGO CONJUGATES TARGETING RAS AND CYCLIN B1: DESIGN AND AN IN VITRO EVALUATION

Hosam Zaghloul*, Ibrahim El-Dosoky, Mahmoud E. El-awady, Fardous F. El-Senduny and Farid A. Badria

ABSTRACT

Background: cancer is the second leading cause of death worldwide. Peptide-oligo conjugates (POC) are certain molecules that can be used as multifunctional therapeutics. Aim: designing POC targeting both Ras family of proteins and Cyclin B1 and evaluating the anticancer activity in vitro. Methods: Five different sequences of POC were designed (POC 1– 5) and tested against the MCF-7 human breast cancer cell lines and the viability of cells was monitored. Results: Two sequences (POC4 and -5) had a potent anticancer activity and resulted in a reduction in viability by 61 and 73%, respectively, when transfected with saponin. Conclusion: Using POC improves synergistic targeting of vital cancer pathways and in turn offers a better outcome in cancer treatment.

Keywords: Breast Cancer, Cyclin B1, POC, Cyclin B1; Ras.